Novartis receives EU approval for Cosentyx label update

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.

The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday.

(Reporting by Silke Koltrowitz)

Related News

BRICS development bank to issue up to $500 million in masala bonds

Mar 30, 2017

US-INDIA-BRICS:BRICS development bank to issue up to $500 million in masala bonds

SEC investor advocate to poll small U.S. investors on new rules

Feb 24, 2017

US-USA-SEC-INVESTORS:SEC investor advocate to poll small U.S. investors on new rules

Analysts see more gains as Amazon shares break $1,000

May 30, 2017

US-AMAZON-COM-STOCKS:Analysts see more gains as Amazon shares break $1,000

Must Read

BRICS development bank to issue up to $500 million in masala bonds

Mar 30, 2017

US-INDIA-BRICS:BRICS development bank to issue up to $500 million in masala bonds

SEC investor advocate to poll small U.S. investors on new rules

Feb 24, 2017

US-USA-SEC-INVESTORS:SEC investor advocate to poll small U.S. investors on new rules

Analysts see more gains as Amazon shares break $1,000

May 30, 2017

US-AMAZON-COM-STOCKS:Analysts see more gains as Amazon shares break $1,000

Search
You May Need To Know

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales@obserworld.com